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. This is an open access article under1. Resource detailsDate of derivation April 2009
Karyotype 46, XX
Sex Female
Pluripotent YES — by Nanog, Oct4, Tra1–60, and SSEA4 staining,
tri-lineage teratoma formation and Alkaline Phosphatase
Disease status Expansion of CAG repeats (23 and 45 CAG repeats) —
Huntington Disease (HD) affected, OMIM: 143100
Sterility The cell line is tested and found negative for Mycoplasma
and any visible contamination2. Materials and methods
2.1. Cell line derivation
The thawed embryowas platedwhole ontomitomycin C inactivated
human feeders (Detroit 551HFF— 90,000 cells perwell in 4well) in 20%
KSR medium with 20 ng/mL FGF added fresh (Amit et al., 2000). CGH
karyotyping and STR proﬁling were performed at the ﬁrst cryobanking
step from ICMoutgrowthsmaintained on feeders. Alkaline Phosphatase
staining was performed on feeders. Cells were then enzymatically pas-
saged as single cells in M2 pluripotent cell maintenance medium
(Genea Biocells) and CGH/karyotyping repeated, immunoﬂuorescent
pluripotent marker staining, pluritest and sterility testing performed.
2.2. Genetic analysis
1. Karyotyping: Passage 4; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
Sibling lines available NOthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Morphology and karyotype of Genea046. A) Alkaline phosphatase activity (passage
3) on human inactivated feeders. B) Karyotypic analysis (passage 4) showing 46, XX
normal, female karyotype.
Table 1
CGH analysis summary; Genea046 (passage 11, 4 enzymatic) reporting a female cell line
and no abnormalities detected.
CGH summary
Sample name Genea046p11_TE4
Date reported 20th September 2012
Hybridisation balance Balanced hybridization was observed for all chromosomes.
Copy number change No copy number changes above 400 kb were detected.
Interpretation Female cell line — no abnormalities detected
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colcemid for 2.5 h. Single cells were subsequently obtained using
Non-Enzymatic Cell Dissociation Solution (Sigma) and transferred
to Sydney IVF's (now Genea) diagnostic cytogenetics laboratory
for preparation of metaphase spreads and cytogenetic analysis by
G-banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome count was performed for 5
and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 11 (7 on feeders, 4 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).
3. DNA Proﬁling: Passage 3; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
2.3. Pluripotency assessment
1. Alkaline Phosphatase: Passage 3; Genea046 grown on feeders was
stained as per manufacturers protocol using the Merck Millipore
Alkaline Phosphatase Detection Kit (SCR004)
2. Immunoﬂuorescence: Passage 11 (7 on feeders, 4 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. Teratoma formation: Passage 8; Stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20%KSR for in-
jection. In both experiments, mice were anaesthetized before intra-
muscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1 × T25) in 50 μL were
injected per mouse at one site only. Resultant teratomas were
excised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
2.4. Sterility testing
1. Mycoplasma: Passage 5; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR
2. Microbial contamination: Testing was performed in conjunction
with our QC measures. Cells were thawed and cultured in 7 mL anti-
biotic free medium (Genea Biocells M2 medium) for 2–3 days at
37 °C. A clear solution at ~48–72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
2.5. Veriﬁcation and authentication
2.5.1. Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryos were fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea046 has been de-
rived from a donated, fully commercially consented embryo, originallycreated by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation andwas declared
excess to reproductive needs. Derivation was performed under
Australian National Health and Medical Research Council (NHMRC) li-
cence 309710. This licence was issued to GENEA on 7 May 2007. More
information about the licence can be obtained from the NHMRC
webpage at http://www.nhmrc.gov.au/health-ethics/human-embryos-
and-cloning/database-licences-authorising-use-excess-art-embryos.
2.5.2. PGD analysis conclusion
Mutation; expansion of CAG (23 and 45 CAG repeats) in HTT gene.
Family tree; Mother has 45 repeats; b inherited from her Mother.
Huntington Disease (HD) affected. See (Bradley et al., 2011) for
sequencing analysis.
2.6. Morphology
The derived stem cell line, Genea046, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A).
2.6.1. Genetic analysis
The cell line has been karyotyped (Fig. 1B, Supplementary Fig. 1) and
also tested by CGH (Table 1, Supplementary Fig. 2), demonstrated 46,
Table 2
STR proﬁle; Genea046 (passage 3) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
SIVF046_p3 10,14 29,30 7,11 10,11 15,18 7,9.3 9,10 11,12 18,24 13.2,14 14,17 8,11 14,18 11,12 20,25
Fig. 2.Pluripotency validation ofGenea046. A) Immunoﬂuorescent staining (10×)of pluripotent cellmarkers SSEA4 (green),Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 11, 4
enzymatic). B) Quantitation of expression of pluripotent markers. C) Tri-lineage teratoma formation (passage 8) with (left) neuroepithelium squamous, (middle) cartilage, gut, salivary,
smooth muscle squamous and (right) renal blastema.
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markers showed Allele pattern consistent with female genotype
(Table 2, Supplementary Fig. 3).
2.6.2. Pluripotency
GENEA046 is pluripotent by;
1. Alkaline Phosphatase stain positivity (Fig. 1A)
2. Immunoﬂuorescence with 85% Nanog positive, 92% Oct4, 75% Tra1–
60 and 99% SSEA4 positive (Fig. 2A, quantiﬁed in 2B).
3. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2C).
2.6.3. Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.021.
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